BioWorld

June 17, 2008

Acadia Sinks as ACP-104 Misses Endpoint in Schizophrenia Trial

Shares of Acadia Pharmaceuticals Inc. plunged 43 percent Monday on news that its experimental schizophrenia drug, ACP-104, failed to meet its primary endpoint of antipsychotic efficacy in a 247-patient Phase IIb study. (BioWorld Today) Read More

Mpex, GSK in Antibiotics Deal Using Efflux Pump Inhibitors

'Circuit Neuromics' Championed as Path to Understanding Mood

Want a Wicked Cool Hat? Try the BioWorld Booth

Exelixis, FDA Set SPA for XL184 Pivotal Study in Thyroid Cancer

Other News To Note

EHA Roundup

Clinic Roundup

Financings Roundup

Today's news in brief

BioWorld

ADPD 2026: Can we prevent dementia? Scientists quantify it

BioWorld

Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...

Illustration of Alzheimer's disease in the brain

ADPD 2026: Three inflection points to target Alzheimer’s disease

BioWorld Science

A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 17, 2026

SERCA inhibitor from Sumitomo shows promise for MSA-C treatment

BioWorld Science

At the ongoing International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2026) in Copenhagen, Sumitomo Pharma Co....